Colin Jacobs, PhD, assistant professor in the Department of Medical Imaging at Radboud University Medical Center in Nijmegen, The Netherlands, and Kiran Vaidhya Venkadesh, a second-year PhD candidate with the Diagnostic Image Analysis Group at Radboud University Medical Center discuss their 2021 Radiology study, which used CT images from the National Lung Cancer Screening Trial (NLST) to train a deep learning algorithm to estimate the malignancy risk of lung nodules.
The bird flu crisis on dairy farms could boost interest in milk protein manufactured in microorganisms and plants.
HiDEF-seq advances cancer treatment:
HiDEF-seq technique could further help develop or advance new prevention approaches or develop treatments for genetic diseases and even cancer.
Gilad Evrony, senior study author and a core member of the Center for Human Genetics & Genomics at NYU Grossman School of Medicine told Science Direct:
The DNA a woman is born with may influence how her cells respond to chromosomal abnormalities acquired with aging, according to a new genomic analysis co-led by NCI researchers.
FDA has granted an accelerated approval to tovorafenib (Ojemda) for kids and teens who have low-grade glioma with changes in the BRAF gene.
Although very rare, past reports show some cancer patients may develop secondary cancers following lifesaving CAR T-cell therapy.
This protocol details the generation of cortical organoids with complex neural oscillations through a ‘semi-guided’ protocol, and their functional characterization using microelectrode array measurements, calcium imaging and adeno-associated virus transduction.
The reason targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked, has been discovered by researchers from UCL, the Francis Crick Institute and AstraZeneca.
The study, published in Nature Communications, shows that lung cancer cells with two particular genetic mutations are more likely to double their genome, which helps them to withstand treatment and develop resistance to it.
In the UK, lung cancer is the third most common type of cancer and the leading cause of cancer death. Around 85% of patients with lung cancer have non-small cell lung cancer (NSCLC), and this is the most common type found in patients who have never smoked. Considered separately, “never smoked” lung cancer is the fifth-most common cause of cancer death in the world.
New research shows that ferroptosis, a form of cell death, occurs in severe COVID-19 patient lungs. Stopping it improves outcomes. In some severe cases of COVID-19, the lungs undergo extreme damage, resulting in a range of life-threatening conditions like pneumonia, inflammation, and acute respiratory distress syndrome. The root cause of those wide-ranging reactions in the lungs has until now remained unclear.
A new study by researchers at Columbia and the Columbia University Irving Medical Center sheds light on this mystery.
The study found that ferroptosis, a form of cell death first named and identified at Columbia in 2012, is the major cell death mechanism that underlies COVID-19 lung disease.
The gene-editing technique employs prime editors along with advanced enzymes known as recombinases. This method has the potential to lead to universal gene therapies that are effective for conditions like cystic fibrosis.
Researchers at the Broad Institute of MIT and Harvard have enhanced a gene-editing technology that can now efficiently insert or replace entire genes in human cell genomes, potentially making it suitable for therapeutic uses.
The advance, from the lab of Broad core institute member David Liu, could one day help researchers develop a single gene therapy for diseases such as cystic fibrosis that are caused by one of hundreds or thousands of different mutations in a gene. Using this new approach, they would insert a healthy copy of the gene at its native location in the genome, rather than having to create a different gene therapy to correct each mutation using other gene-editing approaches that make smaller edits.
